Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 38 results:
Author Title Type [ Year(Desc)]
Filters: Author is Filion, K. B.  [Clear All Filters]
2007
K. B. Filion, Delaney, J. A., Brophy, J. M., Ernst, P., and Suissa, S., “The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database”, Pharmacoepidemiol Drug Saf, vol. 16, pp. 1-4, 2007.
2008
S. S. Daskalopoulou, Delaney, J. A., Filion, K. B., Brophy, J. M., Mayo, N. E., and Suissa, S., “Discontinuation of statin therapy following an acute myocardial infarction: a population-based study”, Eur Heart J, vol. 29, pp. 2083-91, 2008.
2009
K. B. Filion, Joseph, L., Boivin, J. F., Suissa, S., and Brophy, J. M., “Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis”, Pharmacoepidemiol Drug Saf, vol. 18, pp. 973-6, 2009.
2010
L. Azoulay, Schneider-Lindner, V., Dell'Aniello, S., Filion, K. B., and Suissa, S., “Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study”, Pharmacoepidemiol Drug Saf, vol. 19, pp. 343-50, 2010.
2011
K. B. Filion, Joseph, L., Boivin, J. F., Suissa, S., and Brophy, J. M., “Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus”, Pharmacoepidemiol Drug Saf, vol. 20, pp. 785-96, 2011.
2012
L. Azoulay, Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., and Suissa, S., “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study”, Bmj, vol. 344, p. e3645, 2012.
2014
L. L. Lipscombe, Austin, P. C., Alessi-Severini, S., Blackburn, D. F., Blais, L., Bresee, L., Filion, K. B., Kawasumi, Y., Kurdyak, P., Platt, R. W., Tamim, H., and Paterson, J. M., “Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data”, Schizophr Res, vol. 154, pp. 54-60, 2014.
K. B. Filion, Chateau, D., Targownik, L. E., Gershon, A., Durand, M., Tamim, H., Teare, G. F., Ravani, P., Ernst, P., and Dormuth, C. R., “Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis”, Gut, vol. 63, pp. 552-8, 2014.
2015
C. Renoux, Dell'Aniello, S., Saarela, O., Filion, K. B., and Boivin, J. F., “Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study”, BMJ Open, vol. 5, p. e008365, 2015.
J. L. Faillie, Filion, K. B., Patenaude, V., Ernst, P., and Azoulay, L., “Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes”, Diabetes Obes Metab, vol. 17, pp. 379-85, 2015.
O. H. Yu, Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., and Suissa, S., “Incretin-based drugs and the risk of congestive heart failure”, Diabetes Care, vol. 38, pp. 277-84, 2015.
2016
K. B. Filion, Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., Udell, J. A., and Ernst, P., “A Multicenter Observational Study of Incretin-based Drugs and Heart Failure”, N Engl J Med, vol. 374, pp. 1145-54, 2016.
M. Tuccori, Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., and Azoulay, L., “Pioglitazone use and risk of bladder cancer: population based cohort study”, Bmj, vol. 352, p. i1541, 2016.
M. Pang, Schuster, T., Filion, K. B., Eberg, M., and Platt, R. W., “Targeted Maximum Likelihood Estimation for Pharmacoepidemiologic Research”, Epidemiology, vol. 27, pp. 570-7, 2016.
2017
N. Larivee, Suissa, S., Eberg, M., Joseph, L., Eisenberg, M. J., Abenhaim, H. A., and Filion, K. B., “Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study”, Bjog, vol. 124, pp. 1672-1679, 2017.
N. Larivee, Suissa, S., Coulombe, J., Tagalakis, V., and Filion, K. B., “Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters”, Drug Saf, vol. 40, pp. 583-596, 2017.
M. Eberg, Platt, R. W., and Filion, K. B., “The Estimation of Gestational Age at Birth in Database Studies”, Epidemiology, vol. 28, pp. 854-862, 2017.
S. M. Grandi, Vallee-Pouliot, K., Reynier, P., Eberg, M., Platt, R. W., Arel, R., Basso, O., and Filion, K. B., “Hypertensive Disorders in Pregnancy and the Risk of Subsequent Cardiovascular Disease”, Paediatr Perinat Epidemiol, vol. 31, pp. 412-421, 2017.
A. Douros, Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., “Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events”, Diabetes Care, vol. 40, pp. 1506-1513, 2017.
J. Y. Shin, Eberg, M., Ernst, P., and Filion, K. B., “Statin potency and the risk of hospitalization for community-acquired pneumonia”, Br J Clin Pharmacol, vol. 83, pp. 1319-1327, 2017.
2018
B. M. Hicks, Filion, K. B., Yin, H., Sakr, L., Udell, J. A., and Azoulay, L., “Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study”, Bmj, vol. 363, p. k4209, 2018.
A. Mehrabadi, Reynier, P., Platt, R. W., and Filion, K. B., “Domperidone for insufficient lactation in England 2002-2015: A drug utilization study with interrupted time series analysis”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 1316-1324, 2018.
A. Douros, Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., and Azoulay, L., “Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy”, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
O. Yu, Azoulay, L., Yin, H., Filion, K. B., and Suissa, S., “Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia”, Am J Med, vol. 131, pp. 317.e11-317.e22, 2018.
A. Douros, Dell'Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., “Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study”, Bmj, vol. 362, p. k2693, 2018.
S. M. Grandi, Reynier, P., Platt, R. W., Basso, O., and Filion, K. B., “The timing of onset of hypertensive disorders in pregnancy and the risk of incident hypertension and cardiovascular disease”, Int J Cardiol, vol. 270, pp. 273-275, 2018.
2019
A. Douros, Rouette, J., Yin, H., Yu, O. H. Y., Filion, K. B., and Azoulay, L., “Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes”, Diabetes Care, 2019.
M. Eberg, Platt, R. W., Reynier, P., and Filion, K. B., “Estimation of high-dimensional propensity scores with multiple exposure levels”, Pharmacoepidemiol Drug Saf, 2019.
M. H. Secrest, Platt, R. W., Dormuth, C. R., Chateau, D., Targownik, L., Nie, R., Doyle, C. M., Dell'Aniello, S., and Filion, K. B., “Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research”, Pharmacoepidemiol Drug Saf, 2019.
M. H. Secrest, Platt, R. W., Reynier, P., Dormuth, C. R., Benedetti, A., and Filion, K. B., “Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example”, Pharmacoepidemiol Drug Saf, 2019.
C. E. Lefebvre, Filion, K. B., Reynier, P., Platt, R. W., and Zappitelli, M., “Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD”, Clin J Am Soc Nephrol, 2019.
K. B. Filion, Douros, A., Azoulay, L., Yin, H., Yu, O. H., and Suissa, S., “Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study”, Br J Clin Pharmacol, 2019.
2020
F. Khosrow-Khavar, Filion, K. B., Bouganim, N., Suissa, S., and Azoulay, L., “Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study”, Circulation, vol. 141, pp. 549-559, 2020.
F. Khosrow-Khavar, Bouganim, N., Filion, K. B., Suissa, S., and Azoulay, L., “Cardiotoxicity of Sequential Aromatase Inhibitors Use in Women with Breast Cancer”, Am J Epidemiol, 2020.
C. A. Gravel, Filion, K. B., Reynier, P. M., and Platt, R. W., “Postmyocardial Infarction Statin Exposure and the Risk of Stroke with Weighting for Outcome Misclassification”, Epidemiology, vol. 31, pp. 880-888, 2020.
H. T. Ayele, Reynier, P., Azoulay, L., Platt, R. W., Cabaussel, J., Benayoun, S., and Filion, K. B., “Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study”, World J Urol, 2020.
2021
S. M. Grandi, Filion, K. B., Hutcheon, J. A., Rosella, L. C., and Platt, R. W., “Accounting for Repeat Pregnancies in Risk Prediction Models”, Epidemiology, 2021.
V. C. Brunetti, Reynier, P., Azoulay, L., Yu, O. H. Y., Ernst, P., Platt, R. W., and Filion, K. B., “SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study”, Pharmacoepidemiol Drug Saf, 2021.
[Page last reviewed 6 April 2021]